Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units ("RSUs") to one newly hired employee.
馬薩諸塞州查爾斯敦，2024年12月03日（環球新聞通訊社）—— Solid Biosciences公司（納斯達克：SLDB）（"公司"），是一家開發針對神經肌肉和心臟疾病的精準基因藥物的生命科學公司，今天宣佈向一名新僱員授予11,847個限制性股票單位（"RSU"）。
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee's continued service with the Company through each applicable vesting date.
這些RSU將分四個相等的部分在授予日期的每個一年週年日逐步歸屬，直到授予日期的第四個週年日。權益獎勵的歸屬取決於該員工在每個適用歸屬日期繼續爲公司服務。
This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
這項授予是根據公司2024年誘導股票激勵計劃進行的，並作爲該員工接受公司聘用的實質性誘因，符合納斯達克上市規則5635(c)(4)。
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
關於固體生物科學（Solid Biosciences）
Solid Biosciences是一家生命科學公司，專注於推進一系列基因治療候選藥物，包括針對杜氏肌營養不良症（Duchenne）的SGt-003、針對兒茶酚胺多形性室性心動過速（CPVT）的SGt-501、針對TNNT2介導的擴張型心肌病的SGt-601、針對BAG3介導的擴張型心肌病的SGt-401，以及治療致命心臟病的其他資產。Solid正在推進其在稀有神經肌肉和心臟疾病領域的多樣化管線，匯聚科學、科技、疾病管理和護理方面的專家。以患者爲中心，由直接受影響的人員創立，Solid的使命是改善患者在與這些致命疾病鬥爭中的日常生活。更多信息，請訪問。
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Solid Biosciences投資者聯繫方式：
Nicole Anderson
投資者關係和企業傳播董事Nicole Anderson
solid biosciences 公司。
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒體聯繫：
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
Source: Solid Biosciences Inc.
來源：Solid Biosciences Inc.
